Table 3 Blood gas analyses.

From: Nebulized enriched heparin improves respiratory parameters in patients with COVID-19: a phase I/II randomized and triple-blind clinical trial

Analyses / Groups

D0

D2

D5

D7

P value

pH

Placebo

7.4 (0.0)

7.4 (0.0)

7.5 (0.0)

7.4 (0.0)

0.4934##

Heparin

7.5 (0.1)

7.5 (0.0)

7.4 (0.1)

7.4 (0.0)

0.4768##

P value**

0.3675

0.5246

0.1453

0.0182

 

pCO2, mmHg

Placebo

33.7 (6.7)

34.8 (3.7)

34 (2.4)

32.8 (4.3)

0.8246#

Heparin

36.9 (7.6)

36.9 (2.1)

37.6 (5.0)

33.3 (8.7)

0.5139#

P value*

0.3424

0.1878

0.0739

0.8815

 

pO2, mmHg

Placebo

69.5 (20.5)

72.1 (23.7)

71.2 (5.6)

75.6 (13.9)

0.6482##

Heparin

80.4 (30.3)

68.0 (18.6)

71.6 (16.3)

79.2 (18.0)

0.4580##

P value**

0.1564

0.3704

0.8689

0.5638

 

PaO2/FiO2 ratio

Placebo

235.1 (65.2)

240.3 (117.9)

279.5 (160.7)

350.2 (89.9)

0.2432##

Heparin

243.6 (80.2)

253.5 (76.4)

328.6 (69.8)

359.0 (35.4)

0.0316##a

P value**

0.2110

0.4234

0.3213

0.4967

 

SpO2 (%)

Placebo

94.7 (4.3)

95.0 (3.1)

94.2 (1.6)

95.6 (3.1)

0.3429##

Heparin

95.6 (3.2)

94.4 (3.5)

94.5 (2.5)

95.9 (2.3)

0.3633##

P value**

0.0987

0.6058

0.6217

0.8888

 

Lactate, mmol/L

Placebo

1.8 (0.5)

1.6 (0.5)

1.9 (0.4)

1.8 (0.5)

0.5848#

Heparin

1.6 (0.5)

1.8 (0.6)

2.1 (0.7)

1.9 (0.5)

0.2738#

P value*

0.3056

0.4618

0.3925

0.7702

 

HCO3, mEq/L

Placebo

23.6 (7.0)

24.9 (4.6)

23.7 (1.8)

21.6 (3.5)

0.7417##

Heparin

25.7 (5.0)

25.4 (2.8)

25.1 (3.2)

22.7 (3.8)

0.1443##

P value**

0.1823

0.3337

0.3213

0.9849

 

BE, mEq/L

Placebo

0.2 (6.8)

1.5 (4.5)

0.3 (1.2)

-1.8 (2.5)

0.6830##

Heparin

1.5 (4.7)

1.7 (2.5)

1.1 (1.8)

-0.8 (4.5)

0.1402##

P value**

0.3562

0.3336

0.3825

0.9528

 

Oxygen Therapy, lpm

Placebo

2.0 (1.0)

1.0 (2.0)

0.5 (1.8)

0 (0.0)

0.0046##b

Heparin

3.0 (2.0)

1.5 (2.5)

0.0 (0.5)

0.0 (0.0)

0.0001##c

P value**

0.3975

0.4734**

0.1492**

0.8769**